TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04122326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workstation Modification
Description: Participants are asked to work in a sequence of workstation setups for ten minutes each. The sequence include 1. sitting with workstation adjusted by the participant, 2. sitting with workstation adjusted to promote proper posture, 3. sitting with workstation adjusted to promote unnatural posture, 4. standing with workstation adjusted by the participant, 5. standing with workstation adjusted to promote proper posture, and 6. standing with workstation adjusted to promote unnatural posture. After the sequence of setups, the participant allowed to adjust the workstation in either sitting/standing to work in 60 minutes in their own desired position.
Study: NCT04013607

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fructo- and galacto-oligosaccharides
Description: A NDC drink rich in fructo- and galacto-oligosaccharides
Study: NCT05283551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir
Description: Famciclovir (500mg BD)
Study: NCT00677404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM-MNC injection
Description: Bone marrow aspiration A total volume of 400 ml bone marrow will be aspirated from the iliac crest under epidural anaesthesia
Study: NCT03484273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeWrap Compression Garment
Description: Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.
Study: NCT04033367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dupilumab
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study: NCT01960140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally
Study: NCT01759043

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guiding catheter
Description: using a single transradial guiding catheter for coronary angiography and intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic catheter
Description: diagnostic for coronary angiography and guiding catheter selection for intervention
Study: NCT01020786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Induction Therapy: 500 milligrams per square meter (mg/m\^2) given intravenously (IV) on Day 1 of every 21-day cycle for 4 cycles.~Maintenance Therapy: 500 mg/m\^2 given IV on Day 1 of every 21-day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dosage equal to area under the curve (AUC)6 milligrams per milliliter per minute (mg/mL/min) for participant, given IV on Day 1 of every 21-day cycle for 4 cycles.
Study: NCT02939365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: The transition to belatacept monotherapy and possibly to q 8 weeks administration can be safely done by applying personalized (i.e. precision) medicine. This includes phenotypic analysis of lymphocyte subsets, a quiescent molecular profiling of blood and urine prior to drug withdrawal and immune monitoring with KSORT after stepwise withdrawal of steroids and antiproliferatives. Furthermore, trough PK of belatacept will be measured for conversion to q 8 week therapy for discovering research purposes.
Study: NCT03484273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeWrap Compression Garment
Description: Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeWrap Compression Garment
Description: Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.
Study: NCT04280302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based Rehabilitation
Description: VR-based eye stabilization exercises and balance exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Conventional rehabilitation therapy based on eye stabilization exercises and balance exercises
Study: NCT01288521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus + Ketoconazole, Then Tacrolimus alone
Description: Pharmacokinetic profiling of tacrolimus (AUC0-24h) in subjects receiving tacrolimus + ketoconazole 200 mg every 12 hours x 3 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus alone, Then Tacrolimus + Ketoconazole
Description: Pharmacokinetic profiling of subjects on a stable dose of tacrolimus (AUC 0-24h)
Study: NCT01460108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeriSeal System
Description: 20 mL
Study: NCT01018030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FFNS 110 mcg QD
Description: Active Nasal Spray (AM) and Placebo Nasal Spray (PM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FFNS 110 mcg BID
Description: Active Nasal Spray (AM) and Active Nasal Spray (PM)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: Placebo Nasal Spray (AM) and Placebo Nasal Spray (PM)
Study: NCT01536717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine hydrochloride 2% solution
Description: * 4 ml/h periosteal wound infusion~* duration of 72 h
Study: NCT02412410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatigue avoidance education
Description: Grand Rounds presentation of consequences of fatigue and fatigue avoidance techniques
Study: NCT00195091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate
Description: Induction with Tetrathiomolybdate (TM) Tetrathiomolybdate 40 mg. p.o. TID with meals and tetrathiomolybdate 60 mg at bedtime for a total of 4 doses (180 mg) per day.~Induction goal Total tetrathiomolybdate dose per day = 180 mg until serum ceruloplasmin (Cp) level decreases to 5-15mg/dL.~When target Cp window is reached, then the maintenance phase begins.~Maintenance with Tetrathiomolybdate Total tetrathiomolybdate dose per day = 100 mg~Tetrathiomolybdate 40 mg p.o. BID with meals and tetrathiomolybdate 20 mg at bedtime.
Study: NCT02611791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: The application of RF was through Tecatherap-VIP unit (VIP-Eletromedicina, Argentina) with bipolar method, using a gauntlet of 2cm, and the coupling electrode, which was located in the sacral region (fig x). For the application, participants were placed in a supine position with legs in lithotomy position, it was used water soluble gel for coupling and slide of the gauntlet. The application in external labia majora was made in the caudal-cranial direction, with constant movement and electrode lightly pressed. (fig) During the session, the heat level was monitored verbally and by infrared digital thermometer. The intensity was gradually increased, and at the time when the temperature reached values between 39-41ºC, the intensity was reduced two points and the procedure was maintained for two minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Radiofrequency - OFF
Description: The treatment protocol for the control group was identical, differing only in relation to the RF equipment, which was turned off, but a water-soluble gel was used, heated by a resistor, preventing the patient from knowing to which group she belonged. Just the physiotherapist who performed the procedure knew which group the patient belonged to.
Study: NCT01536717

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Placebo Sodium chloride 0,9%
Study: NCT04579146

Intervention type: OTHER
Intervention: coronary computed tomographic angiographic (CCTA)
Description: x-ray examination with contrast by a 64-slice CT coronary angiography.
Study: NCT04440267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Asparaginase
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor
Description: acute lymphoblastic leukemia (ALL) -based chemotherapy
Study: NCT01582061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide sub-cutaneous
Description: Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg, 600 μg, or 300 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg and 600 μg for glucose impaired metabolism patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide sub-cutaneous
Description: Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg, 600 μg, or 300 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg and 600 μg for glucose impaired metabolism patients
Study: NCT01255423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium topical gel 1%
Description: Diclofenac sodium topical gel 1%, 4 times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 4 times daily
Study: NCT04072913

Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal samples (biopsies + vaginal smear)
Description: Two types of samples are envisaged: tissue (large biopsies, coin of conization or hysterectomy) to affirm the diagnosis and detect the matrix metalloproteinases and their tissue inhibitors by immunohistochemistry; cell sample (monolayer smear type) to evaluate the expression of oncogenic Human papillomavirus.

Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal samples (biopsies + vaginal smear)
Description: Two types of samples are envisaged: tissue (large biopsies, coin of conization or hysterectomy) to affirm the diagnosis and detect the matrix metalloproteinases and their tissue inhibitors by immunohistochemistry; cell sample (monolayer smear type) to evaluate the expression of oncogenic Human papillomavirus.

Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal samples (biopsies + vaginal smear)
Description: Two types of samples are envisaged: tissue (large biopsies, coin of conization or hysterectomy) to affirm the diagnosis and detect the matrix metalloproteinases and their tissue inhibitors by immunohistochemistry; cell sample (monolayer smear type) to evaluate the expression of oncogenic Human papillomavirus.

Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal samples (biopsies + vaginal smear)
Description: Two types of samples are envisaged: tissue (large biopsies, coin of conization or hysterectomy) to affirm the diagnosis and detect the matrix metalloproteinases and their tissue inhibitors by immunohistochemistry; cell sample (monolayer smear type) to evaluate the expression of oncogenic Human papillomavirus.
Study: NCT03567772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wiifit Nintendo video game

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program
Study: NCT03498950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: laser irradiation on the taste papillae
Study: NCT01404507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gp 2b 3a inhibitor
Description: bolus injection of abciximab via intracoronary route single injection during primary PCI dosage : 0.25mg/kg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: aspiration thrombectomy
Description: Aspiration thrombectomy via aspiration catheter

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Both use
Description: Both use of intracoronary abciximab and aspiration thrombectomy
Study: NCT00815217

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection of lipoaspirate
Description: Small volume lipoaspiration will be performed. This technique involves harvesting small amounts of fat by making a small incision in the donor site (usually the abdomen) and infiltrating 25-75cc of tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) into the adipose layer with a blunt infiltrator. The Coleman aspiration Cannulae, approximately 2-3 mm in diameter and 15 cm in length attached with a Luer-Lok suction syringe will be used to harvest up to 100 cc of fat. Gently pulling back on the syringe provides a small amount of negative pressure to allow for aspiration into the syringe.For the intervention wound, the adipose tissue will be implanted using the infiltration Cannulae (blunt end, 7 cm- COL-17) or the both approx. 1mm in diameter. The implantation will be in single tunnels radially around each wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
Study: NCT04591938

Intervention type: DEVICE
Group type: OTHER
Intervention: Fantom Encore Bioresorbable scaffold implantation
Description: Fantom Encore Bioresorbable scaffold implantation
Study: NCT03211468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical intervention program to prevent eating disorders
Description: See previous
Study: NCT02218684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidipine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00702468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: containing delta-9-tetrahydrocannabinol (THC)(27 mg/ml):cannabidiol (CBD)(25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Dose: 100 µl oromucosal spray, as required for symptom relief

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains no active drug and is delivered in 100 microlitre actuations by a pump action oromucosal spray
Study: NCT01994642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sterile Otic Suspension
Study: NCT03512834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10mg/kg, administered via I.V infusion over 1hour, every 2weeks until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2 D1,8 and 15 , administered via I.V infusion, every 4 weeks.
Study: NCT01701206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV knowledge Intervention
Study: NCT01612975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Intervention arm involves administering 500mg Naproxen BID to participants and 40mg of Pantoprazole in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert, inactive placebo pill similar in appearance to naproxen allocation. To be taken twice daily for 4 weeks total along with 40mg pantoprazole.
Study: NCT04598022

Intervention type: OTHER
Intervention: cross-sectional observation
Description: observation of dietary patterns, body weight status, microbiome and metabolome profiles at the start of the first semester

Intervention type: OTHER
Intervention: cross-sectional observation
Description: observation of dietary patterns, body weight status, microbiome and metabolome profiles at the start of the first semester

Intervention type: OTHER
Intervention: cross-sectional observation
Description: observation of dietary patterns, body weight status, microbiome and metabolome profiles at the start of the first semester

Intervention type: OTHER
Intervention: cross-sectional follow-up observation
Description: follow-up observation of dietary patterns, body weight status,microbiome and metabolome profiles after one year

Intervention type: OTHER
Intervention: cross-sectional follow-up observation
Description: follow-up observation of dietary patterns, body weight status,microbiome and metabolome profiles after one year

Intervention type: OTHER
Intervention: cross-sectional follow-up observation
Description: follow-up observation of dietary patterns, body weight status,microbiome and metabolome profiles after one year
Study: NCT00160186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancreatin
Description: 2 capsules Pancreatin with 25 000 lipase units per main meal (3 meals) and 1 capsule per snack (2-3 snacks)
Study: NCT03070249

Intervention type: BEHAVIORAL
Intervention: Professional Quality of Life (ProQoL) scale
Description: COMPASSION SATISFACTION AND COMPASSION FATIGUE (PROQOL) measures how compassion for those who are cared for can affect providers in positive and negative ways. Questions about experiences, both positive and negative, as a provider reflecting the frequency experiences within the last 30 days. 1=Never 2=Rarely 3=Sometimes 4=Often 5=Very Often
Study: NCT02210403

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Study: NCT00160186

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00232622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streptokinase
Description: Accelerated infusion of streptokinase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Streptokinase
Description: Standard dose streptokinase
Study: NCT02190136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein whole foods
Description: Protein-rich whole foods consumed at 20-30 grams of protein at each of 4-6 meals per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein whole foods
Description: Protein-rich whole foods consumed at 20-30 grams of protein at each of 4-6 meals per day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein whole foods
Description: Protein-rich whole foods consumed at 20-30 grams of protein at each of 4-6 meals per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein Resistance Exercise Training
Description: Protein rich whole foods diet and resistance training 3 times per week for 11 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein Resistance Exercise Training
Description: Protein rich whole foods diet and resistance training 3 times per week for 11 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein Stretching/Yoga Training
Description: Protein-rich whole foods diet of 20-30 grams of protein at each of 4-6 meals per day with stretching/yoga training 3 times per week for 11 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein Stretching/Yoga Training
Description: Protein-rich whole foods diet of 20-30 grams of protein at each of 4-6 meals per day with stretching/yoga training 3 times per week for 11 weeks
Study: NCT05089006

Intervention type: PROCEDURE
Intervention: Partial nephrectomy with robot-assisted and open surgery
Description: Robot-assisted partial nephrectomy (RAPN) is considered as a feasible minimally invasive alternative to open partial nephrectomy (OPN) for the surgical treatment of renal tumors. The main advantages of this technique include a three-dimensional magnified view of the surgical field, enhanced dexterity, and greater precision in both dissection and reconstruction.

Intervention type: PROCEDURE
Intervention: Partial nephrectomy with robot-assisted and open surgery
Description: Robot-assisted partial nephrectomy (RAPN) is considered as a feasible minimally invasive alternative to open partial nephrectomy (OPN) for the surgical treatment of renal tumors. The main advantages of this technique include a three-dimensional magnified view of the surgical field, enhanced dexterity, and greater precision in both dissection and reconstruction.